49 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences. He is also a member of European Molecular Biology Organization
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
Peter Ratcliffe was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences. He is also a member of European Molecular
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
at the 2022 European Society for Medical Oncology (ESMO) Congress in September 2022. Durable Response Evaluation Criteria in Solid Tumors (RECIST
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
-small cell lung, and endometrial carcinoma. The initial data from the Phase 1 clinical trial of IMC-F106C was presented at the 2022 European Society
10-K
2023 FY
EX-10.12
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
of the Venture Capital Engagement Committee of the National Multiple Sclerosis Society and will continue to do so without the need for prior approval
8-K
EX-99.2
88bm6f
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
6-K
EX-99.2
nzzgnpb7jcvmxv2j
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
f35x10
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
dlbe40f4
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
mnddu to3
10 Aug 23
Current report (foreign)
8:28am
6-K
c2dm si92
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
lfst4rva
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.3
jvb7jf 9wjf
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
o86jhx3gnl
10 May 23
Current report (foreign)
7:27am
6-K
ex02rgo7qgg0 ekpi32v
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.1
kkqksd8y7s5158ztcgu
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.3
g57n2hm01mjtjv2
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
udhlewq68m93rk1s l1
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
3dkx46nplra72is
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
pnzi4
9 Sep 22
Prospectus supplement for primary offering
4:23pm